Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278

Similar articles for PubMed (Select 23849704)

1.

Tissue-selective estrogen complexes for postmenopausal women.

Mirkin S, Komm BS.

Maturitas. 2013 Nov;76(3):213-20. doi: 10.1016/j.maturitas.2013.06.003. Epub 2013 Jul 11. Review.

PMID:
23849704
2.

Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.

Pickar JH, Mirkin S.

Menopause Int. 2010 Sep;16(3):121-8. doi: 10.1258/mi.2010.010033. Review.

PMID:
20956688
3.

Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.

Pinkerton JV, Pickar JH, Racketa J, Mirkin S.

Climacteric. 2012 Oct;15(5):411-8. doi: 10.3109/13697137.2012.696289. Epub 2012 Aug 1. Review.

PMID:
22853444
4.

The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.

Kagan R.

J Womens Health (Larchmt). 2012 Sep;21(9):975-81. doi: 10.1089/jwh.2011.3448. Epub 2012 Jul 3. Review.

PMID:
22759213
5.

Treating menopausal symptoms with a tissue-selective estrogen complex.

Levine JP.

Gend Med. 2011 Apr;8(2):57-68. doi: 10.1016/j.genm.2011.03.008. Review.

PMID:
21536225
6.

Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.

Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S.

Maturitas. 2014 Jul;78(3):212-8. doi: 10.1016/j.maturitas.2014.04.008. Epub 2014 Apr 26. Erratum in: Maturitas. 2014 Dec;79(4):488.

PMID:
24837362
7.

Tissue selective estrogen complex combinations with bazedoxifene/conjugated estrogens as a model.

Pinkerton JV, Komm BS, Mirkin S.

Climacteric. 2013 Dec;16(6):618-28. doi: 10.3109/13697137.2013.810437. Epub 2013 Jun 27. Review.

PMID:
23805785
8.

Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.

Bachmann G, Bobula J, Mirkin S.

Climacteric. 2010 Apr;13(2):132-40. doi: 10.3109/13697130903305627.

PMID:
19863455
9.

Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).

Lindsay R.

Osteoporos Int. 2011 Feb;22(2):447-51. doi: 10.1007/s00198-010-1440-x. Epub 2010 Nov 11. Review.

PMID:
21069294
10.

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.

Komm BS, Mirkin S, Jenkins SN.

Steroids. 2014 Nov;90:71-81. doi: 10.1016/j.steroids.2014.06.004. Epub 2014 Jun 11.

PMID:
24929044
11.

Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.

Mirkin S, Ryan KA, Chandran AB, Komm BS.

Maturitas. 2014 Jan;77(1):24-31. doi: 10.1016/j.maturitas.2013.10.009. Epub 2013 Oct 25. Review.

PMID:
24246155
12.

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G.

Fertil Steril. 2009 Sep;92(3):1025-38. doi: 10.1016/j.fertnstert.2009.03.113. Epub 2009 Jul 26.

PMID:
19635615
13.

Advances in menopausal therapy: the tissue-selective estrogen complex.

Moore A.

J Am Assoc Nurse Pract. 2013 Mar;25(3):126-33. doi: 10.1111/j.1745-7599.2012.00804.x. Epub 2012 Nov 26. Review.

PMID:
24218199
14.

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy.

Komm BS, Mirkin S.

Int J Womens Health. 2012;4:129-40. doi: 10.2147/IJWH.S29346. Epub 2012 Mar 28.

15.

Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.

Pinkerton JV, Stovall DW.

Expert Opin Investig Drugs. 2010 Dec;19(12):1613-21. doi: 10.1517/13543784.2010.532487. Epub 2010 Nov 13. Review.

PMID:
21073353
16.

Selective estrogen modulators in menopause.

Gambacciani M.

Minerva Ginecol. 2013 Dec;65(6):621-30.

PMID:
24346250
17.

Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture.

Rossini M, Lello S, Sblendorio I, Viapiana O, Fracassi E, Adami S, Gatti D.

Drug Des Devel Ther. 2013 Jul 22;7:601-10. doi: 10.2147/DDDT.S47807. Print 2013.

18.

The tissue selective estrogen complex: a promising new menopausal therapy.

Komm BS, Mirkin S.

Pharmaceuticals (Basel). 2012 Sep 4;5(9):899-924. doi: 10.3390/ph5090899.

19.

Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms.

Archer DF.

Drugs Aging. 2010 Jul 1;27(7):533-44. doi: 10.2165/11316000-000000000-00000. Review.

PMID:
20583848
20.

Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.

Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Racketa J, Shi H, Chines AA, Mirkin S.

J Womens Health (Larchmt). 2014 Jan;23(1):18-28. doi: 10.1089/jwh.2013.4392. Epub 2013 Nov 9.

PMID:
24206058
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk